Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Collaboration to Develop Diagnostic Products

By Labmedica staff writers
Posted on 29 Jun 2005
Under a recently announced agreement, Biosite (San Diego, CA, USA) has received a license to develop and commercialize immunoassay-based diagnostic products using novel biomarkers discovered by Compugen Ltd. More...
(Tel Aviv, Israel). Using its genomic platform and other proprietary computational tools, Compugen is expected to provide Biosite with comprehensive data on several gene targets to be nominated by BioSite.

Under the terms of the agreement, Compugen gives Biosite an exclusive license to use the selected Compugen targets for immunoassay-based diagnostic applications. In return, Compugen is to receive milestone payments and royalties from the sales of each diagnostic product emerging from the alliance. Compugen retains the exclusive right to pursue further development in the therapeutic field, and Biosite will be entitled to receive from Compugen any milestone payments and royalties arising from a successful therapeutic application.

This collaboration combines Biosite's expertise in rapid, high-affinity antibody development and commercialization of proprietary testing platforms, consisting of both individual diagnostic markers and panels of markers, with Compugen's discovery capabilities. This discovery process relies on the comprehensive predictive analysis of the human proteome provided by the company's genomic platform. The result of this analysis is utilized with various discovery engines, each designed to identify novel proteins with specific characteristics from the vast numbers predicted by the discovery process.

"We hope that this partnership will enable access to novel markers in areas of strategic focus to Biosite that will lead to new product opportunities for us,” stated Gunars Valkirs, Ph.D., senior vice president, discovery, at BioSite.

"We are excited about the opportunity to collaborate with BioSite, a leading provider of rapid diagnostic products and antibody-development technologies,” said Mor Amitai, president and CEO of Compugen.





Related Links:
Compugen
BioSite

New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Laboratory Software
ArtelWare
New
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.